OBJECT To evaluate the efficacy and survival rate of entecavir treatment for chronic liver failure patients with hepatitis *** 116 chronic liver failure patients with hepatitis B were treated with entecavir 0.5mg dail...
详细信息
OBJECT To evaluate the efficacy and survival rate of entecavir treatment for chronic liver failure patients with hepatitis *** 116 chronic liver failure patients with hepatitis B were treated with entecavir 0.5mg daily and other routine *** 58 hepatitis B patients with chronic liver failure were treated with only routine drugs as *** liver functions,hepatitis B virus DNA level,prothrombin time activity and the survival rate were *** comparison of rates were done using chi-square *** numeration data were compared by t *** survival rates were compared using Kaplan-Meier *** At the 4 weeks,8 weeks and 12 weeks of the treatment,ALT
Advanced liver disease,which includes cirrhosis and hepatocellular carcinoma(HCC),is a serious problem in *** order to elucidate the status of these diseases,the medical records of 317 HCC patients and 62 liver cirrho...
详细信息
Advanced liver disease,which includes cirrhosis and hepatocellular carcinoma(HCC),is a serious problem in *** order to elucidate the status of these diseases,the medical records of 317 HCC patients and 62 liver cirrhosis patients were studied and a comparative analysis was *** the HCC patients,89.0%of cases were due to hepatitis B virus(HBV),8.2%cryptogenic and only 2.8%of cases were hepatitis C virus(HCV)*** contrast,11.3%and 9.7%of cases of cirrhosis were cryptogenic or HCV-related respectively,while HBV-related cases accounted for 79.0%The majority of patients were in their *** HBV-related HCC patients were the youngest and had the highest percentage of *** HCC patients had the highest levels of platelets,ALT and AST,and the lowest rate of *** with patients with HCC having severe fibrosis in noncancerous tissues,those with HCC and milder fibrosis were younger and had a lower rate of HBeAb positivity,a higher rate of HBsAb positivity and higher platelet *** and AFP levels,male gender and HBcAb positivity were the four risk factors for development of HCC among HBV-related cirrhosis patients.
暂无评论